Treatment Practices for Castration-Sensitive Prostate Cancer

Updated safety findings may support the ARASAFE regimen as a potential standard of care in metastatic hormone-sensitive prostate cancer.

Experts weigh in on the practical applications of PSMA PET imaging

Data from the AMPLITUDE trial may support widespread genomic testing at diagnosis to inform targeted therapy strategies for those with CSPC.

Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.

Imaging developments have made it possible to detect nodal recurrence at low PSA levels, which could help guide salvage approaches for prostate cancer.

RLT-based combinations, RLTs across genitourinary cancers, and RLTs in earlier lines of therapy are among the considerations for further research.